EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • MET exon 14 mutation • RET mutation • MET mutation • KRAS G12 • EGFR negative • NTRK fusion

GC101 TIL

10d

ATATcH Alternating Treatment Plans for Advanced Cancer (clinicaltrials.gov)

P2, N=150, Recruiting, Rutgers, The State University of New Jersey | Trial completion date: Dec 2025 --> May 2028 | Trial primary completion date: May 2025 --> May 2027

10 days ago

Trial completion date • Trial primary completion date

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • MET exon 14 mutation • MET mutation • ALK translocation

Keytruda (pembrolizumab) • carboplatin • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed

11d

HLX43-NSCLC201: A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)

P2, N=243, Recruiting, Shanghai Henlius Biotech | N=41 --> 243

11 days ago

Enrollment change

BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

PD-L1 expression • EGFR mutation • MET exon 14 mutation

HLX43

11d

TROPION-Lung17: Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations (clinicaltrials.gov)

P3, N=400, Recruiting, AstraZeneca

11 days ago

Trial initiation date

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

KRAS G12C • MET exon 14 mutation • KRAS G12

docetaxel • Datroway (datopotamab deruxtecan-dlnk)

16d

POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC (clinicaltrials.gov)

P1, N=19, Active, not recruiting, Institute of Cancer Research, United Kingdom | Recruiting --> Active, not recruiting

16 days ago

Enrollment closed

MET (MET proto-oncogene, receptor tyrosine kinase)

MET exon 14 mutation • MET mutation

Keytruda (pembrolizumab) • Tepmetko (tepotinib)

17d

Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC (clinicaltrials.gov)

P2, N=19, Not yet recruiting, Shanghai Chest Hospital

17 days ago

New P2 trial

KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

KRAS G12C • MET amplification • ALK rearrangement • MET exon 14 mutation • MET overexpression • ROS1 rearrangement • MET mutation • KRAS G12 • ALK negative

vebreltinib (APL-101)

17d

A Study of TAK-505 in Adults With Solid Tumors (clinicaltrials.gov)

P1/2, N=151, Recruiting, Takeda | Not yet recruiting --> Recruiting

17 days ago

Enrollment open • First-in-human

BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

PD-L1 expression • MSI-H/dMMR • BRAF V600 • MET exon 14 mutation • RAS wild-type • EGFR positive

20d

Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung Cancer. (PubMed, Cancer Res Commun)

Serial pCGP can inform treatment decisions in patients with NSCLC. In those with EGFR-mutant disease, pCGP at progression identifies actionable drivers of therapy resistance, enabling therapeutic intervention.

20 days ago

Journal

EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • MET (MET proto-oncogene, receptor tyrosine kinase)

BRAF V600E • EGFR mutation • BRAF V600 • MET exon 14 mutation

25d

NAPISTAR1-01: FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC (clinicaltrials.gov)

P1/2, N=174, Recruiting, Tubulis GmbH | N=120 --> 174

25 days ago

Enrollment change • Platinum resistant • First-in-human

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FOLR1 ( Folate receptor alpha ) • SLC34A2 (Solute carrier family 34 member 2) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF V600E • EGFR mutation • KRAS G12C • BRAF V600 • RET fusion • MET exon 14 mutation • ALK mutation • RET mutation • ROS1 fusion • MET mutation • KRAS G12 • NTRK fusion

25d

P3, N=400, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

25 days ago

Enrollment open

KRAS G12C • MET exon 14 mutation • KRAS G12

docetaxel • Datroway (datopotamab deruxtecan-dlnk)

27d

PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung (clinicaltrials.gov)

P2, N=60, Active, not recruiting, Duke University | Trial completion date: Mar 2026 --> Nov 2026

27 days ago

Trial completion date

EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

MET exon 14 mutation

Libtayo (cemiplimab-rwlc) • Praluent (alirocumab)